Navigation Links
OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
Date:5/14/2009

ival benefit of OGX-011, anticipated clinical development activities, timing of these activities, the ability of future trials to demonstrate clinical benefit and the potential for regulatory approvals. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements.

The potential risks and uncertainties associated with forward-looking statements include, among others, the possibility that any benefit in patient survival will not be maintained or will become less substantial as patient survival follow up continues, risks that clinical trials will not be successful or confirm earlier clinical trial results, including the risk that the survival benefit will not be confirmed by a Phase 3 clinical trial, risks associated with obtaining funding from third parties or completing a financing necessary to support the costs and expenses of a Phase 3 clinical trial, the timing and costs of clinical trials and regulatory approvals will be different than management currently anticipates, risks relating to the development, safety and efficacy of therapeutic drugs and potential applications for these products and the risk factors set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for fiscal year 2008. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
2. OncoGenex Reports First Quarter Financial Results
3. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
4. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
5. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
6. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
7. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
8. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
9. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
10. OncoGenex Reports Third Quarter Financial Results
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Wendel – recipient of a Regional Top Doctor Award for ... Surgeon Specialists for Nashville, TN – has released a new ... Hydration Booster, Retexturing Night Crème, and Anti-aging C Complex, all ... radiant appearance while protecting them from the sun’s harmful UV ... Dr. J. J. Wendel Plastic Surgery, we have developed a ...
(Date:7/29/2014)... , July 29, 2014 ... System (LBS) zur Erfassung biologischer Daten in ... entwickelt und patentiert. Das LBS nimmt gleichzeitig ... Koronararterie des Patienten und sucht erhöhte biologische ... das Potenzial, die Entdeckung und Entwicklung neuer ...
(Date:7/28/2014)... 28, 2014 The Workgroup for Electronic ... the use of health IT to create efficiencies in ... Identifier (HPID) Workgroup has developed an issue brief ... and Payer?” The HPID Workgroup, a part of WEDI’s ... Centers for Medicare and Medicaid Services (CMS) to identify ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Proove ... medicine, will be exhibiting data and research conducted through ... International Spine Intervention Society’s (ISIS) 22nd Annual Scientific ... at the Hyatt Regency, in Orlando, Florida. ... and clinical competence of physicians who care for patients ...
Breaking Biology Technology:Dr. J. J. Wendel Launches New Line of Skin Care Products 2PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 2PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 3PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 4WEDI’s HPID Workgroup Announces Release of Issue Brief: “What is the Difference Between a Health Plan and Payer?” 2Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting 2
... An effective team of advisors can help an entrepreneur make ... as a corporate attorney, I know that finding advisors who ... advisors effectively, can be challenging for entrepreneurs. , ,In a ... the law firm Michael Best & Friedrich , I ...
... print still captures the imagination of consumers - even consumers ... clearer example than Blurb . I first discussed Blurb ... than a brief PowerPoint deck. We met at ... unwound a vision for consumer-generated books that well pre-dates the ...
... Hearn Madison, Wis. - The total ... business case for a software implementation, but it might ... are defending their turf. , ,The ability to establish ... fundamental understanding of the business, might be the difference ...
Cached Biology Technology:Tapping the value of entrepreneurial advisors 2Tapping the value of entrepreneurial advisors 3Blurb shows that print still captures imaginations 2Blurb shows that print still captures imaginations 3CIOs focus on the business case while facing 'authority erosion' 2CIOs focus on the business case while facing 'authority erosion' 3
(Date:7/28/2014)... showing signs of damage from the Deepwater Horizon oil spill ... Gulf of Mexico. The discovery was made by a team ... University. A paper describing this work and additional impacts of ... be published during the last week of July 2014 in ... the National Academy of Sciences . , "The footprint of ...
(Date:7/28/2014)... Essigmann and colleagues from the University of Washington had a ... could induce the virus to mutate uncontrollably, they could force ... that our immune system uses against many viruses. , ... mutate at an enhanced rate, as expected. But it did ... trial reported in 2011. In a new study, however, Essigmann ...
(Date:7/28/2014)... Alzheimer,s disease and other forms of dementia, but the ... , University of Washington bioengineers have a designed a ... the body,s normal proteins into a state that,s linked ... Type 2 diabetes and Lou Gehrig,s disease. The synthetic ... normal state into an abnormally folded form by targeting ...
Breaking Biology News(10 mins):Impact of Deepwater Horizon oil spill on coral is deeper and broader than predicted 2Forced mutations doom HIV 2Forced mutations doom HIV 3Forced mutations doom HIV 4New protein structure could help treat Alzheimer's, related diseases 2New protein structure could help treat Alzheimer's, related diseases 3
... from the University California, San Diego (UCSD) Branch of ... Systems have developed an efficient method to identify thousands ... a study published today in Nature. , Genes are ... Thus the 'promoter' - a DNA sequence that controls ...
... States have found evidence of lichen-like symbiosis in 600-million-year-old ... lichen was 400 million years old, discovered in Scotland. ... of fungi and raises new questions about lichen evolution. ... of Geology and Palaeontology; Shuhai Xiao, assistant professor of ...
... Asian tsunami tragedy should be allowed to recover naturally ... some of the world's leading scientists. , The scientists, ... upon Tyne, and who set out their views in ... historical records of major coral reef devastation by cyclones ...
Cached Biology News:Whole genome promoter mapping - Human Genome Project v2.0? 2Evidence of 600-million-year old fungi-algae symbiosis discovered in marine fossils 2Evidence of 600-million-year old fungi-algae symbiosis discovered in marine fossils 3Tsunami-damaged coral reefs should be left to recover naturally, say scientists 2
Rabbit polyclonal to GABA A Receptor gamma 2 ( Abpromise for all tested applications). entrezGeneID: 2566 SwissProtID: P18507...
... Cyclin D2 is a G1 cyclin ... strong candidate for a proto-oncogene. cyclin ... cdk4 and/or cdk6. Species Reactivity: Human, ... NeoMarkers DCS-3.1 MAb is particularly well suited ...
Mouse monoclonal [4A2.2] to SLC6A4 ( Abpromise for all tested applications). entrezGeneID: 6532 SwissProtID: P31645...
V beta 5 Purified Anti-Human clone MH3-2, Isotype Mouse IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
Biology Products: